#China #Shanghai #gastric cancer #Satri-cel #CARsgen Therapeutics

Introduction

At the European Society for Medical Oncology (ESMO) Congress 2026, CARsgen Therapeutics Holdings Limited made significant strides in the treatment landscape of gastric cancer with the presentation of preliminary results from their trial on satricabtagene autoleucel, known as 'satri-cel'. This groundbreaking therapy specifically targets Claudin18.2, addressing a crucial unmet need for patients diagnosed with locally advanced gastric or gastroesophageal junction cancer. The trial, officially designated CT041-CG4010 and registered under NCT06857786, shows promise as an adjuvant treatment carried out after curative surgery.

Study Overview

The prognosis for high-risk patients with locally advanced gastric cancer following a curative gastrectomy is often bleak. With only 73-78% of patients achieving a disease-free survival (DFS) rate at the one-year mark, and a sharp decline to 58-64% at two years, the necessity for innovative therapeutic strategies is prominent. The CT041-CG4010 trial involved participants who had undergone a radical gastrectomy with D2 lymphadenectomy, featuring pathologically confirmed cases of either (y)pT4aN+ or T4bNany diseases.

The design of the study included a primary emphasis on safety. Secondary endpoints ranged from assessing the treatment's efficacy to analyzing pharmacokinetics of the infused product. At the cut-off data on September 14, 2026, ten patients were treated with satri-cel. All individuals had T4a or T4b classification with node-positive diseases, of which a considerable 80% were determined as N2/N3 stage, indicating an exceedingly high risk of postoperative recurrence.

Results

Among the ten patients, seven completed at least twelve months of follow-up after their surgeries. Remarkably, none exhibited signs of postoperative recurrence or metastasis. The data revealed a 100% DFS rate at the twelve-month mark, indicating profound success, with the median DFS yet to be established. One patient initially identified as minimal residual disease (MRD)-positive transitioned to a negative status post-infusion, which remained consistently negative during follow-ups.

The pharmacokinetics data showed robust CAR T-cell expansion across all patients, underscoring the therapy's biological efficacy. In terms of safety, the incidence of cytokine release syndrome (CRS) stood at 80%, categorized as grade 1-2 in severity, with an average recovery time of four days. Encouragingly, no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) appeared, and no fatalities linked to adverse events were reported. The overall safety profile of satri-cel in this context proves to be manageable and auspicious.

Expert Insights

Dr. Zonghai Li, the founder and CEO of CARsgen, expressed optimism regarding the results, emphasizing the superior potential of satri-cel as a pioneering option in an area of significant need for high-risk gastric cancer patients post-surgery. He noted, "The findings suggest that satri-cel may effectively address residual disease and could influence patient outcomes positively, reinforcing our commitment to advancing this therapy into earlier treatment stages."

About Satri-cel

Satri-cel represents a trailblazing therapeutic approach as the first-in-class CAR T-cell therapy targeting Claudin18.2, having gained approval in June 2026 for patients with HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma who have experienced failure after two previous lines of therapy. The company continues to expand satri-cel's indications, exploring its application in earlier treatment contexts such as adjuvant and sequential therapies for gastric cancer, encapsulating an ambitious dedication to widen the horizon of curative options available for patients.

Conclusion

CARsgen Therapeutics is sweeping the stage with its innovative CAR T-cell therapy, Satri-cel, setting the foundation for a new era in gastric cancer treatment. As research continues to unfurl, the promise held by satri-cel could pave the way for transformative advancements in cancer care, assuring hope for countless patients battling this challenging disease. The journey of CARsgen's pioneering efforts denotes a collective stride towards elevating patient lives through novel therapeutic avenues.